Health Capital Helsinki
  • Home
  • Why Helsinki Metropolitan
  • About
  • News
  • Events
  • Opportunities
  • Careers
  • Contact
  • Search
  • Menu Menu
Janne Hirvonen / Helsinki Partners
Feb 13, 2023

Helsinki-based TILT Biotherapeutics raises EUR 22 million to advance cancer therapies

TILT Biotherapeutics, a clinical-stage biotechnology company from Finland developing cancer immunotherapies, has closed a EUR 22 million financing round led by Finland’s Lifeline Ventures.

Of this final close of EUR 22 million, Helsinki-based TILT Biotherapeutics raised EUR 10 million in June 2022. The financing was led by Finland’s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs.

This second round of EUR 12 million includes EUR 5.9 million from the European Innovation Council (EIC) Fund as well as a EUR 2.1 million grant from EIC’s Accelerator programme. The EIC Fund is TILT’s first significant international investor.

The funding will be used to advance to Phase II the company’s combination trials which use oncolytic immunotherapies synergistically with checkpoint inhibitors.

“We’re pleased to have achieved this round of EUR 22 million to advance our promising pipeline of armed oncolytic viruses. Our trials are progressing well through Phase I, and this new funding will support us in progressing them into Phase II, another key step for these new therapies to reach patients in a range of cancers”, says TILT Biotherapeutics’ founder and CEO Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients with oncolytic viruses.

Read more

News

Health Capital Helsinki

Close-up of unrecognizable woman using nasal sprayMarko Verch / Flickr

Researchers developed a potential key for future pandemics

Mar 31, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2023/03/Woman-nasal-spray_Flickr-1500x1000-1.jpg 1001 1500 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-03-31 12:47:332023-03-31 12:49:24Researchers developed a potential key for future pandemics
MVision AI software on a laptopMVision AI

Helsinki-based MVision AI raises EUR5.4M to speed up cancer treatment

Mar 27, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2023/03/MVision-image-w1200.jpg 675 1200 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-03-27 15:16:222023-03-29 14:41:55Helsinki-based MVision AI raises EUR5.4M to speed up cancer treatment
Two researchers in white coats walkingKeksi Agency via City of Helsinki

TILT Biotherapeutics, rising superstar of oncolytic immunotherapy

Mar 21, 2023
https://healthcapitalhelsinki.fi/wp-content/uploads/2020/04/Keksi-Agency-via-City-of-Helsinki_communications.jpg 1653 2480 taruvirtanen https://healthcapitalhelsinki.fi/wp-content/uploads/2020/02/hch_logo_horizontal_black-300x165-1.png taruvirtanen2023-03-21 08:00:272023-03-29 15:04:22TILT Biotherapeutics, rising superstar of oncolytic immunotherapy
More news

Health Capital Helsinki

Helsinki Partners
Kasarmikatu 36
00130 HELSINKI
FINLAND

Privacy notice

Sign up to our newsletter

Subscribe

Follow us

  • twitter
  • linkedin
Health Capital Helsinki
Scroll to top

We use cookies to give you the best experience on our website.

Find out more and set your preferences settings.

Powered by  GDPR Cookie Compliance
How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential website cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are necessary to deliver the website as intended, refusing them will have impact how our site functions. You can always block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will prompt you to accept or refuse cookies every time you revisit our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Third party cookies

This website uses Twitter's and LinkedIn's cookies to help us improve our content and reach.

Please enable essential website cookies first so that we can save your preferences!

Privacy notice

You can read about how we use your data on our Privacy notice page.

Privacy notice